- Home
- CVKD vs ATHE Comparison
CVKD vs ATHE Comparison
Compare CVKD & ATHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ATHE
- Stock Information
- Founded
- CVKD 2022
- ATHE 1997
- Country
- CVKD United States
- ATHE Australia
- Employees
- CVKD N/A
- ATHE N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ATHE Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ATHE Health Care
- Exchange
- CVKD Nasdaq
- ATHE Nasdaq
- Market Cap
- CVKD 20.8M
- ATHE 21.4M
- IPO Year
- CVKD 2023
- ATHE N/A
- Fundamental
- Price
- CVKD $19.72
- ATHE $4.75
- Analyst Decision
- CVKD Strong Buy
- ATHE Strong Buy
- Analyst Count
- CVKD 1
- ATHE 2
- Target Price
- CVKD $32.00
- ATHE $8.00
- AVG Volume (30 Days)
- CVKD 51.3K
- ATHE 1.3M
- Earning Date
- CVKD 03-10-2025
- ATHE 02-15-2025
- Dividend Yield
- CVKD N/A
- ATHE N/A
- EPS Growth
- CVKD N/A
- ATHE N/A
- EPS
- CVKD N/A
- ATHE N/A
- Revenue
- CVKD N/A
- ATHE $2,681,669.00
- Revenue This Year
- CVKD N/A
- ATHE N/A
- Revenue Next Year
- CVKD N/A
- ATHE N/A
- P/E Ratio
- CVKD N/A
- ATHE N/A
- Revenue Growth
- CVKD N/A
- ATHE 2.63
- 52 Week Low
- CVKD $5.40
- ATHE $1.00
- 52 Week High
- CVKD $21.30
- ATHE $5.87
- Technical
- Relative Strength Index (RSI)
- CVKD 59.55
- ATHE 75.45
- Support Level
- CVKD $19.07
- ATHE $2.76
- Resistance Level
- CVKD $19.56
- ATHE $5.14
- Average True Range (ATR)
- CVKD 1.48
- ATHE 0.42
- MACD
- CVKD 0.01
- ATHE 0.15
- Stochastic Oscillator
- CVKD 69.69
- ATHE 71.14
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About ATHE Alterity Therapeutics Limited
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.